News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Teva Pharmaceutical Industries Limited Introduces First Generic Lamictal(R) Tablets in the United States
July 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial shipment of its generic version of Lamictal® (Lamotrigine) Tablets, 25mg, 100 mg, 150 mg, and 200 mg.
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
August 10, 2026
·
2 min read
·
Nick Paul Taylor
Cancer
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
August 4, 2026
·
2 min read
·
Tristan Manalac
China
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
July 28, 2026
·
7 min read
·
Annalee Armstrong
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
July 27, 2026
·
10 min read
·
Heather McKenzie